Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba

 
• By Neena Brizmohun
  
obese heart
The EMA is reviewing the cardiovascular risk with obesity drug Mysimba • Source: Shutterstock

More from Europe

More from Geography